Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 07:31 am
Share
Chunghwa Chemical Synthesis & Biotech Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 526.44 million compared to TWD 579.4 million a year ago. Net income was TWD 29.6 million compared to TWD 147.89 million a year ago. Basic earnings per share from continuing operations was TWD 0.38 compared to TWD 1.91 a year ago. Diluted earnings per share from continuing operations was TWD 0.38 compared to TWD 1.9 a year ago.
For the six months, sales was TWD 1,291.89 million compared to TWD 1,108.93 million a year ago. Net income was TWD 208.85 million compared to TWD 275.56 million a year ago. Basic earnings per share from continuing operations was TWD 2.69 compared to TWD 3.55 a year ago. Diluted earnings per share from continuing operations was TWD 2.68 compared to TWD 3.52 a year ago.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.